stockrowOutlook Therapeutics, Inc.
OTLK Healthcare Biotechnology
Outlook Therapeutics, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $1.4 million.
- Revenue
- −99.4%
- EPS
- +72.7%
- Free cash flow
- −76.5%
- Total debt
- −47.1%
Quarter to June 2026, against a year earlier
Follow OTLK
Alert me
Outlook Therapeutics, Inc. (OTLK) EV/Sales
As of 6 November 2026, Outlook Therapeutics, Inc. (OTLK) trades at a EV/Sales of −66.1×. Over the past ten years it has ranged from −219× (July 2026) to 507× (June 2026); the current reading is higher than 3% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.1× | 171.77% |
| FY2019 | 3.7× | (78.68%) |
| FY2018 | 17.4× | 51.96% |
| FY2017 | 11.5× | (53.85%) |
| FY2016 | 24.8× | 35.67% |
| FY2015 | 18.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −202× | — |
| Mar 2026 | 109× | 361.35% |
| Dec 2025 | 23.7× | 134.88% |
| Sep 2025 | 10.1× | 2.26% |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OTLK Outlook Therapeutics, Inc. | −66.1× |
| NBP NovaBridge Biosciences compare | −5.3× |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| VYGR Voyager Therapeutics, Inc. compare | 0.4× |
| HUMA Humacyte, Inc. compare | 41.4× |
| ARMP Armata Pharmaceuticals, Inc. compare | 69.2× |
| ANIX ANIXA BIOSCIENCES INC compare | 101× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)